These included intermediate (5–10 MU/m2), low (≤3 MIU/m2), and very low (1 MIU/m2) dosing regimens, and the trials are summarized in Table 2 (Table 2—phase III studies of IFN-α for metastatic melanoma). The gene discussed is IFNA1; the disease is metastatic melanoma.